Mimrylo (rusfertide) NDC 63020-725

NDC codes

FDA NDC Directory

Product NDC (as listed)63020-725Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63020-0725Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63020-725-20	63020072520	1 KIT in 1 CARTON (63020-725-20) * 19 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (63020-720-20) * .6 mL in 1 SYRINGE (63020-600-05)Marketed from Aug 28, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mimrylo
Generic name (nonproprietary): rusfertide
Dosage form: Kit
Route: Subcutaneous
Labeler: Takeda Pharmaceuticals America, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 220605
Marketing start: Aug 28, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 63020-725_2fc41c37-8a81-4171-a52c-e9317c0c34cfSPL ID 2fc41c37-8a81-4171-a52c-e9317c0c34cfSPL set ID 101aff01-31ed-4841-a8b6-0a5a8503189bRxCUI 2751601, 2751606, 2751608, 2751610, 2751612, 2751614, 2751616, 2751618, 2751620, 2751622

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N463020072520 followed by a unit qualifier and the quantity

Package 63020-0725-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 28, 2026.

Indications (excerpt from the label)

MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is a hepcidin mimetic indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 220605

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 220605
Product	Strength	Form · route	Labeler	Product NDC
Mimrylorusfertide	—	KitSubcutaneous	Takeda Pharmaceuticals America, Inc.	63020-735
Mimrylorusfertide	—	KitSubcutaneous	Takeda Pharmaceuticals America, Inc.	63020-715
Mimrylorusfertide	—	KitSubcutaneous	Takeda Pharmaceuticals America, Inc.	63020-745
Mimrylorusfertide	—	KitSubcutaneous	Takeda Pharmaceuticals America, Inc.	63020-765